New‐onset guttate psoriasis secondary to COVID‐19

Rouai, Meriem; Rabhi, Faten; Mansouri, Nada; Jaber, K.; Dhaoui, Raouf

doi:10.1002/ccr3.4542

Cited by 10 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a novel coronavirus named as SARS‐CoV‐2 triggering an outbreak of coronavirus disease 2019 (COVID‐19) at the end of 2019. A few new‐onset psoriasis were reported in the context of COVID‐19 infection 55,56 . Stimulation of toll‐like receptor 3 by viral RNA, causing dysregulation of innate immune response and production of IL‐36‐γ and CXCL8 may be the possible pathogenesis of COVID‐19 infection leading to psoriasis, 49,57–59 and the hyperinflammatory state of COVID‐19 may exacerbate psoriasis 49,60 .…”

Section: Discussionmentioning

confidence: 99%

“…A few new‐onset psoriasis were reported in the context of COVID‐19 infection. 55 , 56 Stimulation of toll‐like receptor 3 by viral RNA, causing dysregulation of innate immune response and production of IL‐36‐γ and CXCL8 may be the possible pathogenesis of COVID‐19 infection leading to psoriasis, 49 , 57 , 58 , 59 and the hyperinflammatory state of COVID‐19 may exacerbate psoriasis. 49 , 60 Moreover, COVID‐19 infection can trigger inflammatory cytokine storms involving both the innate and the cellular adaptive immunity, which play a critical role in the pathogenesis of liver disease and exacerbate steatohepatitis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bioinformatics analysis to reveal the potential comorbidity mechanism in psoriasis and nonalcoholic steatohepatitis

Xian,

Bai,

Guo

et al. 2023

Skin Research and Technology

View full text Add to dashboard Cite

PurposeAn increasing amount of evidence suggests that psoriasis and nonalcoholic steatohepatitis (NASH) may occur simultaneously, whereas the underlying mechanisms remain unclear. Our research aims to explore the potential comorbidity mechanism in psoriasis and nonalcoholic steatohepatitis.Materials and MethodsThe expression profiles of psoriasis (GSE30999, GSE13355) and NASH (GSE24807, GSE17470) were downloaded from GEO datasets. Next, common differently expressed genes (DEGs) of psoriasis and NASH were investigated. Then, GO and KEGG enrichment, protein interaction network (PPI) construction, and hub gene identification for DEGs were performed. Finally, immune cells expression, target genes predicted by common miRNAs, and transcription factors interaction analysis for hub genes were carried out.ResultsTwenty DEGs were identified in totally. GO analysis revealed response to the virus was the most enriched term, and hepatitis C and coronavirus disease‐COVID‐19 infection‐associated pathways were mainly enriched in KEGG. A total of eight hub genes were collected, including IFIT1, IFIT3, OAS1, HPGDS, IFI27, IFI44, CXCL10, IRF9, and 11 TFs were predicted. Then, neutrophils and monocytes were identified as immune cells that express the most hub genes. Moreover, five common miRNAs for psoriasis and NASH and one common miRNAs (hsa‐miR‐1305)‐mRNAs (CHL1, MBNL2) network were presented.ConclusionCHL1 and MBNL2 may participate in the process of psoriasis and NASH via regulating hsa‐miR‐1305, and together with eight hub genes may be potential therapeutic targets for future treatment for the co‐occurrence of these two diseases. This comprehensive bioinformatic analysis provides new insights on molecular pathogenesis and identification of potential therapeutic targets for the co‐occurrence of them.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis to reveal the potential comorbidity mechanism in psoriasis and nonalcoholic steatohepatitis

Xian,

Bai,

Guo

et al. 2023

Skin Research and Technology

View full text Add to dashboard Cite

show abstract

“…Apart from exacerbations in psoriasis patients, new-onset psoriasis diagnoses were also established following COVID-19 infection. Either drugs administered for COVID-19 or the infection itself might be incriminated for these situations ( 22 , 23 ). On the other hand, the continued psoriasis treatment regimens might explain the absence of any flares in the patients who had COVID-19 in our series.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study

Kaya,

Keskinkaya,

Mermutlu

et al. 2023

Infect Dis Clin Microbiol

View full text Add to dashboard Cite

Objective: Psoriasis patients may have been affected by COVID-19 differently than the normal population due to using different types of treatments, including immunosuppressive agents and biological therapies, the probability of lower effectiveness, and different side effects of the vaccines. This study aimed to evaluate the epidemiologic and clinical features of COVID-19 and the effect of the psoriasis treatment on it. Materials and Methods: Psoriasis patients followed up in our clinic between March 2020 and July 2022 were evaluated in terms of clinicodemographic characteristics, treatment methods, and COVID-19 vaccination status and compared regarding COVID-19 history. Results: A total of 110 patients (female:male ratio=1:1.2) with a mean age of 45.6±14.3 years were evaluated. Thirty patients (27.2%) developed COVID-19 during psoriasis treatment. Unvaccinated patients had COVID-19 (6/11, 55%) more frequently than vaccinated ones (24/99, 24%), but it was not statistically significant (p=0.067). Although patients who received biological therapy were also more frequently infected with SARS-CoV-2 than patients who received other types of therapies (18/53 [34%] versus 12/57 [21%], respectively), the difference was again not statistically significant. A patient with hypertension using acitretin was hospitalized for pulmonary involvement because of COVID-19. No exacerbation of psoriasis was observed in patients who developed COVID-19, while psoriasis flares occurred following COVID-19 mRNA vaccination in two patients. Conclusion: Patients with psoriasis should get vaccinated against COVID-19, as vaccination prevents the disease and does not result in serious side effects. Although using biological agents for the treatment of psoriasis could be related to a higher risk of getting COVID-19, these agents do not increase the risk of severe COVID-19. Therefore, they may be beneficial in reducing the risk of both psoriasis exacerbations and severe COVID-19 due to the cytokine storm among patients using biological for psoriasis. However, large-scale and controlled studies are needed to support our conclusions. Keywords: anti-TNF, biological drugs, COVID-19, immunosuppressive drugs, psoriasis, treatment

show abstract

“…Since the start of the COVID-19 pandemic, several cases of COVID-19 related new-onset psoriasis have been reported. [2][3][4][5][6][7] Most COVID-19 infection-related psoriasis were guttate psoriasis and acute generalized pustular psoriasis, which are very well known to be triggered by viral infection. However, new-onset plaque psoriasis following COVID-19 infection was limited.…”

Section: Psoriasis Is a Chronic T-cell Mediated In Ammatory Diseasementioning

confidence: 99%

New-onset Plaque Psoriasis Following COVID-19 Infection

Yoo,

Gatmaitan,

Yoo

et al. 2023

JKSP

View full text Add to dashboard Cite

show abstract

New‐onset guttate psoriasis secondary to COVID‐19

Cited by 10 publications

References 8 publications

Bioinformatics analysis to reveal the potential comorbidity mechanism in psoriasis and nonalcoholic steatohepatitis

Bioinformatics analysis to reveal the potential comorbidity mechanism in psoriasis and nonalcoholic steatohepatitis

COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study

New-onset Plaque Psoriasis Following COVID-19 Infection

Contact Info

Product

Resources

About